

AMENDMENTS TO THE CLAIMS

1. (**Currently Amended**) An HLA-E chimeric molecule that when expressed in a nonhuman mammal cell, is expressed at the cell surface and that possesses one of ~~possessing~~ the following amino acid ~~sequences~~ sequence:

(1) an HLA-E chimeric molecule (a) replacing all ~~or part~~ of the α 2 domain of an HLA-E molecule with all ~~or part~~ of an α 2 domain of an HLA-G1 molecule or (b) replacing a part of the α 2 domain of the HLA-E molecule including serine 147 with a corresponding part of the α 2 domain of the HLA-G1 molecule including cysteine 147,

(2) an HLA-E chimeric molecule replacing, ~~together with (1),~~ the signal peptide (SP) of an HLA-E molecule with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO:21, and ~~partly reforming the SP of HLA-G1 molecule, or~~ (a) replacing all of the α 2 domain of the HLA-E molecule with all of an α 2 domain of an HLA-G1 molecule or (b) replacing a part of the α 2 domain of the HLA-E molecule with a corresponding part of an α 2 domain of an HLA-G1 molecule, and

(3) an HLA-E chimeric molecule replacing, ~~together with (2),~~ the signal peptide (SP) of an HLA-E molecule with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO:21, and replacing a part of ~~amino acid sequence of the~~ α 1 domain including serine 11 and all or part of the α 2 domain of the HLA-E molecule, with a corresponding part of ~~amino acid sequence of the~~ α 1 domain including alanine 11 and all or a corresponding part of the amino acid ~~sequence of the~~ α 2 domain of an HLA-G1 molecule, ~~respectively.~~

2. (Withdrawn) A base sequence for coding any HLA-E chimeric molecule of claim 1.

3. (Withdrawn) A nonhuman mammal cell or nonhuman mammal animal transformed by the base sequence of claim 2.

4. (Withdrawn) The HLA-E chimeric molecule of claim 1, wherein the SP of HLA-E molecule is replaced with the reformed SP, and serine of amino acid number 147 of α 2 domain of HLA-E

molecule is replaced with cysteine of amino acid number 147 of $\alpha 2$ domain of HLA-G1 molecule.

5. (Withdrawn) The HLA-E chimeric molecule of claim 1, wherein the SP of HLA-E molecule is replaced with the reformed SP, and serine of amino acid number 11 of $\alpha 1$ domain of HLA-E molecule and serine of amino acid number 147 of $\alpha 2$ domain of the same are replaced with alanine of amino acid number 11 of $\alpha 1$ of HLA-G1 molecule and cysteine of amino acid number 147 of $\alpha 2$ of the same, respectively.
6. (New) The HLA-E chimeric molecule of claim 1, wherein the entire $\alpha 2$ domain of the HLA-E chimeric molecule is replaced with the entire $\alpha 2$ domain of the HLA-G1 molecule.
7. (New) The HLA-E chimeric molecule of claim 1, wherein the latter part of the $\alpha 2$ domain of the HLA-E chimeric molecule is replaced with the latter part of the $\alpha 2$ domain of the HLA-G1 molecule.
8. (New) The HLA-E chimeric molecule of claim 1, wherein the first portion of the latter part of the $\alpha 2$ domain of the HLA-E chimeric molecule is replaced with the first portion of the latter part of the $\alpha 2$ domain of the HLA-G1 molecule.
9. (New) The HLA-E chimeric molecule of claim 1, possessing the sequence of an HLA-E chimeric molecule replacing serine 147 of the $\alpha 2$ domain of an HLA-E molecule with cysteine 147 of the $\alpha 2$ domain of the HLA-G1 molecule.
10. (New) The HLA-E chimeric molecule of claim 1, possessing the sequence of an HLA-E chimeric molecule replacing serine 11 of the $\alpha 1$ domain of an HLA-E molecule with alanine 11 of the $\alpha 1$ domain of the HLA-G1 molecule.